Mixed-lineage leukemia (MLL)/AF4-positive ALL is associated with a poor prognosis even after allogeneic hematopoietic SCT (allo-HSCT). We reported previously that MLL/AF4-positive ALL shows resistance to TNF-a, which is the main factor in the GVL effect, by upregulation of S100A6 expression followed by interference with the p53-caspase 8-caspase 3 pathway in vitro. We examined whether inhibition of S100A6 can induce an effective GVL effect on MLL/AF4-positive ALL in a mouse model. MLL/AF4-positive ALL cell lines (SEM) transduced with lentiviral vectors expressing both S100A6 siRNA and luciferase (SEM-Luc-S100A6 siRNA) were produced. SEM-Luc-S100A6 siRNA cells and SEM-Luc-control siRNA cells were injected into groups of five SCID mice (1 Â 10 7 /body). After confirmation of engraftment of SEM cells by in vivo imaging, the mice in each group were injected with 4.8 Â 10 7 human PBMCs. SEM-Luc-S100A6 siRNA-injected mice showed significantly longer survival periods than SEM-Luc-control siRNA-injected mice (P ¼ 0.002). SEM-Luc-S100A6 siRNA-injected mice showed significantly slower tumor growth than those injected with SEM-Luc-control siRNA (Po0.0001). These results suggested that inhibition of S100A6 may be a promising therapeutic target for MLL/AF4-positive ALL in combination with allo-HSCT.
INTRODUCTION
Rearrangements of the mixed-lineage leukemia (MLL) gene located at 11q23 are common chromosomal abnormalities associated with acute leukemia, especially infant leukemia and secondary leukemia following treatment with DNA topoisomerase II inhibitors. In addition, 11q23/MLL abnormalities are now widely recognized as important prognostic factors in acute leukemia. Over 70 chromosomal partners of 11q23 have been identified to date, at least 50 of which have been cloned and characterized at the molecular level. 1 The prognosis of leukemia patients with MLL rearrangement varies widely depending on the partner gene, leukemia cell lineage, age of the patient, and treatment administered. 1 The most prevalent MLL rearrangement in ALL generates the MLL/AF4 fusion gene due to a t(4;11)(q21;q23) chromosomal translocation. Despite recent improvements in the overall treatment outcome for ALL patients, including allogeneic hematopoietic SCT (allo-HSCT), MLL/AF4-positive ALL is still associated with a poor prognosis. 2 One reason why MLL/AF4-positive ALL is resistant to allo-HSCT is that MLL/AF4-positive ALL escapes from TNF-a-mediated apoptosis, which is the main GVL effect, by upregulating the expression of S100A6. 3, 4 S100A6 is a 10.5-kDa Ca 2 þ -binding protein belonging to the S100 protein family, which has been reported to interact with and alter the conformation of p53. [5] [6] [7] [8] Upregulation of S100A6 expression in MLL/AF4-positive ALL inhibits p53 acetylation followed by inhibition of upregulation of the caspase 8-caspase 3 apoptotic pathway in the presence of TNF-a. 4 The present study was performed to examine whether inhibition of S100A6 induces GVL effects in an MLL/AF4-positive ALL in vivo model.
MATERIALS AND METHODS

Cell culture
The MLL/AF4-positive ALL cell line SEM was purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA). The SEM cells were maintained in DMEM-high glucose (Sigma, St Louis, MO, USA) supplemented with 10% fetal bovine serum (PAN Biowest, Nuaillé , France) at 37 1C in an atmosphere of 5% CO 2 in air.
Establishment of MLL/AF4-positive ALL cell lines expressing both S100A6 siRNA and luciferase First, we produced MLL/AF4-positive ALL cell line (SEM) transduced with lentiviral vectors express luciferase (SEM-Luc) as described previously. 9 Second, to examine the long-term effects of S100A6 inhibition, we produced SEM-Luc transduced with lentiviral vectors expressing S100A6 siRNA (SEM-Luc-S100A6 siRNA). As a control, SEM-Luc transduced with lentiviral vectors expressing control siRNA were produced (SEM-Luc-control siRNA). The methods used for establishment of SEM-Luc-S100A6 siRNA and SEM-Luc-control siRNA were as described previously. monitored in real-time with an ABI PRISM 7700 sequence detection system (PE Applied Biosystems), thereby allowing determination of the threshold cycle at which exponential amplification of PCR products began. The threshold cycle values for cDNAs corresponding to b-actin and target genes were used to calculate the abundance of the target transcripts relative to that of b-actin mRNA. The oligonucleotide primers of S100A6 were as described previously. 4 In vitro analysis of cell growth of SEM-Luc-S100A6 siRNA and SEM-Luc-control siRNA
The generated leukemia cell lines (SEM-Luc-S100A6siRNA and SEM-Luccontrol siRNA) were incubated in vitro with or without TNF-a (0, 1, 10 and 100 ng/mL) for 48 h before counting cells to examine the effects of TNF-a on leukemia cells, as described previously. 
Murine transplantation experiments and in vivo imaging
The protocol for murine transplantation experiments is shown in Figure 1 . For in vivo analysis, 1 Â 10 7 /body of SEM-Luc-S100A6 siRNA cells or SEMLuc-control siRNA cells were injected into groups of five SCID mice by IP. Twenty-one days after injection of SEM cells, confirmation of engraftment of SEM cells was performed using an in vivo imaging system (IVIS); mice in each group were injected with 4.8 Â 10 7 /body of human PBMCs by IP. In addition to OS rate, tumor growth 21 days after injection of human PBMCs was assessed by IVIS, as described previously. 9 Each mouse was killed at the time of dying or over day 100 on survival. All animal experiments were performed in accordance with the regulations established by the Ethical Committee of Nippon Medical School and were approved by the Animal Care and Committee of Nippon Medical School.
Examination of serum concentrations of human TNF-a by ELISA
The serum concentrations of human TNF-a three weeks after injection of human PBMCs were measured by ELISA in each group of five mice. ELISA was performed as described previously. 11 
Statistical analysis
The results of cell growth and gene expression assays were analyzed by Student's t-test, assuming unequal variances and two-tailed distributions. Data are shown as the means ± s.d. of at least three samples. For survival analyses, event time distributions were estimated using the method of Kaplan and Meier, and differences in survival rates were compared using the log-rank test. In all analyses, Po0.05 was taken to indicate statistical significance.
RESULTS
The expression of S100A6 mRNA was inhibited only in SEM-Luc-S100A6 siRNA cells under 5 ng/mL of TNF-a.
RQ-PCR analysis showed that S100A6 mRNA expression was significantly inhibited in SEM-Luc-S100A6 siRNA cells (P ¼ 0.005) in comparison with those in SEM-Luc-control siRNA cells under 5 ng/mL of TNF-a (Figure 2 ). SEM-Luc-S100A6 siRNA cells were sensitive to TNF-a, while SEM-Luc-control siRNA cells showed resistance There were no significant differences between the growth of SEM-Luc-S100A6 siRNA and SEM-Luc-control siRNA cells in vitro without TNF-a (P ¼ 0.890) (Figure 3a) . However, the growth of SEM-Luc-S100A6 siRNA cells was significantly inhibited by TNF-a in comparison with SEM-Luc-control siRNA cells (P ¼ 0.012 for 1 ng/mL of TNF-a, P ¼ 0.005 for 10 ng/mL of TNF-a and P ¼ 0.012 for 100 ng/mL of TNF-a) (Figure 3b ). No significant differences in serum concentration of human TNF-a were observed between SEM-Luc-S100A6 siRNA-injected and SEM-Luc-control siRNA-injected mice In the in vivo analysis, there were no significant differences between the serum concentrations of human TNF-a 3 weeks after injection of human PBMCs in SEM-Luc-S100A6 siRNA-injected mice and SEM-Luc-control siRNA-injected mice (145.0±5.0 vs 150.0 ± 40.0 pg/mL, respectively, P ¼ 0.95) (Figure 4a ).
Significant differences in tumor growth were observed between SEM-Luc-S100A6 siRNA-injected mice and SEM-Luc-control siRNA-injected mice Although there were no significant differences in tumor size between SEM-Luc-S100A6 siRNA-injected mice and SEM-Luc-control siRNA-injected mice (2.59 ± 0.15 Â 10 5 vs 3.45 ± 0.22 Â 10 5 p/s, respectively, P ¼ 0.52), there were significant differences in tumor size 3 weeks after injection of human PBMCs (6 weeks after SEM cell engraftment) between these two groups (2.98 ± 0.80 Â 10 5 vs 2.54 ± 0.63 Â 10 6 p/s, respectively, Po0.0001) (Figure 4b ). SEM-Luc-S100A6 siRNA-injected mice showed significantly longer OS than SEM-Luc-control siRNA-injected mice Figure 4c shows the OS curves of SEM-Luc-S100A6 siRNA-injected mice and SEM-Luc-control siRNA-injected mice. The difference in OS between the two groups of mice was significant (median 4100 days vs median 54 days, respectively, P ¼ 0.002).
Macropathology of SEM-Luc-S100A6 siRNA-injected mice and SEM-Luc-control siRNA-injected mice Figures 5a and b show the macropathology of SEM-Luc-control siRNA-injected mice and SEM-Luc-S100A6 siRNA-injected mice. Although SEM-Luc-control siRNA-injected mice showed massive tumors and splenomegaly on day 42 after SEM cell injection, no such tumors were observed in SEM-Luc-S100A6 siRNA-injected mice even on day 100 after SEM cell injection.
Micropathology of SEM-Luc-S100A6 siRNA-injected mice and SEM-Luc-control siRNA-injected mice Histopathological analysis showed disruption of the spleen structure ( Figure 5e ) and infiltration of the liver and spleen by lymphoma cells in SEM-Luc-control siRNA-injected mice (Figures 5c and e) in comparison with those in SEM-Luc-S100A6 siRNA-injected mice (Figures 5d and f) .
DISCUSSION
The results of the present study indicate that inhibition of S100A6 can induce the GVL effect in MLL/AF4-positive ALL in a mouse model. We reported previously that MLL/AF4-positive ALL cell lines are resistant to TNF-a, which is the main factor involved in the GVL effect, by upregulation of S100A6 via inhibition of upregulation of the p53-caspase 8-caspase 3 pathway. 4 The results of this study together with our previous findings suggest that inhibition of S100A6 may be a promising therapeutic target for MLL/AF4-positive ALL in combination with allo-HSCT because it induces GVL effects on MLL/AF4-positive ALL, which is otherwise resistant to GVL.
In an in vivo study, we used SCID mice which have functional natural killer (NK) cells without any conditioning. Therefore we previously examined whether only NK cells of SCID mice could inhibit or reject SEM-Luc-S100A6 siRNA cells. The results of that study are shown in Figure 6 . Only NK cells of SCID mice could not inhibit the growth of SEM-Luc-S100A6 siRNA cells. This result showed that the inhibition of growth of SEM-Luc-S100A6 siRNA cells in PBMC-SCID mice is mainly due to human PBMCs. Interestingly, Spijkers-Hagelstein et al. 12 reported that overexpression of the S100 protein family members S100A8 and S100A9 in MLL/AF4-positive ALL was associated with failure to induce free-cytosolic Ca 2 þ and prednisolone resistance. These worthy data together with those of the present study suggest that high expression levels of S100 proteins by MLL/AF4-positive ALL may be the main factors in therapy resistance and poor prognosis of MLL/AF4-positive ALL.
The incidence of MLL/AF4-positive ALL shows a major peak in early infancy, which accounts for over 50% of ALL cases in infants less than 6 months of age; 10-20% of cases occur in older infants, 2% in children and up to 7% in adults. [13] [14] [15] [16] Although the 5-year OS of childhood ALL patients has improved to as much as 90% due to progress in chemotherapy and other supporting therapeutic modalities, including allo-HSCT, 17 the prognosis is still poor for the remaining 10% of cases, which consist mainly of MLL/AF4-positive ALL and Ph chromosome-positive ALL. As use of BCR-ABL tyrosine kinase inhibitors targeting Ph chromosome-positive ALL has been explored, MLL/AF4-positive ALL is the greatest obstacle to overcoming childhood ALL.
Our results suggest that the development of drugs targeting S100 proteins may lead to improvements in MLL/AF4-positive ALL, which is the greatest obstacle to overcoming childhood ALL.
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